Company Overview

PharmaCielo Ltd. is a Canada-based life sciences company focused on the cultivation, extraction, and commercialization of medicinal cannabis products, with primary operations in the medical cannabis and cannabis-derived pharmaceutical ingredient industries. The company’s core business has historically centered on producing cannabis oil extracts intended for regulated medical markets, rather than adult-use recreational sales. Its principal revenue drivers have been bulk cannabis oil, isolates, and derivative products supplied to licensed distributors and pharmaceutical or medical partners.

The company’s strategic positioning has been based on low-cost cultivation and extraction capabilities in Latin America, particularly Colombia, supported by favorable climate conditions and regulatory frameworks for medical cannabis. PharmaCielo was founded in 2014 and became publicly listed in 2018 through a reverse takeover transaction, positioning itself early among Canadian-listed issuers pursuing international medical cannabis supply strategies. Since inception, the company has faced evolving regulatory, financing, and market challenges, and aspects of its operational continuity have been subject to restructuring and liquidity constraints; where disclosures conflict across reporting periods, data is inconclusive based on available public sources.

Business Operations

PharmaCielo’s operations have primarily been conducted through its Colombian subsidiaries, notably PharmaCielo Colombia Holdings S.A.S., which has overseen cultivation, extraction, and processing activities. The company’s business model has focused on vertical integration, encompassing licensed cultivation of cannabis plants, extraction into cannabis oils, and formulation of intermediate products for export into regulated international medical markets. Revenue generation has depended on wholesale supply agreements and export permits rather than branded consumer sales.

Operationally, the company has reported activities in both Canada (corporate, regulatory, and capital markets functions) and Colombia (agricultural and production assets). Its asset base has included cultivation land, extraction facilities, and intellectual property related to processing methods. Disclosures across filings indicate that operational scale and continuity have fluctuated over time due to capital availability, regulatory approvals, and market demand, and some operational details remain inconclusive based on publicly available information.

Strategic Position & Investments

PharmaCielo’s stated strategic direction has emphasized participation in the global medical cannabis supply chain by leveraging low-cost production in emerging markets to serve higher-value international jurisdictions. Growth initiatives historically included expanding licensed cultivation acreage, increasing extraction capacity, and securing export approvals for cannabis derivatives destined for pharmaceutical and medical customers.

The company has pursued this strategy primarily through internal investment in its Colombian operations rather than through large-scale acquisitions, with PharmaCielo Colombia Holdings S.A.S. representing its most significant subsidiary investment. While management disclosures have referenced interest in pharmaceutical-grade inputs and emerging cannabinoid-based therapeutics, the extent of commercial deployment in advanced pharmaceutical applications is unclear, and data regarding sustained investment in emerging technologies is inconclusive based on available public sources.

Geographic Footprint

PharmaCielo’s geographic footprint has been anchored in South America, with operational activities concentrated in Colombia, where cultivation and extraction licenses have been held. Colombia has served as the company’s primary production hub due to climate advantages and export-oriented medical cannabis regulations.

Corporate headquarters and public company functions have been based in Canada, reflecting its listing on the TSX Venture Exchange and access to North American capital markets. Beyond Latin America and North America, the company has disclosed intentions and limited activities related to exports into Europe and other international medical cannabis markets, though the scale and consistency of these international sales have varied and are not fully verifiable across all reporting periods.

Leadership & Governance

PharmaCielo was founded by industry entrepreneurs seeking early exposure to international medical cannabis markets, with governance structured around a Canadian public company board overseeing foreign operating subsidiaries. Leadership disclosures across regulatory filings and public statements indicate changes in executive management over time, reflecting the company’s restructuring and operational challenges.

Key executives identified in the most recent publicly available disclosures include:

• David Attard – Executive Chairman
• Henning von Koss – Chief Executive Officer
• Peter Nedoshytko – Chief Financial Officer

Management has articulated a leadership philosophy centered on regulatory compliance, cost-efficient production, and long-term participation in pharmaceutical and medical cannabis supply chains. However, due to leadership transitions and inconsistent disclosures across periods, certain details regarding executive tenure and responsibilities are inconclusive based on available public sources.